The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Zhi Peng
No Relationships to Disclose
 
Changzheng Li
No Relationships to Disclose
 
Linzhi Lu
No Relationships to Disclose
 
Xiang Wang
No Relationships to Disclose
 
Jun Zhang
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Ting Deng
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Dongyan Cai
No Relationships to Disclose
 
Yin Jin
No Relationships to Disclose
 
Hong Zong
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Huiting Xu
No Relationships to Disclose
 
Mingjun Zhang
No Relationships to Disclose
 
Jianzhi Liu
Employment - RemeGen Co., Ltd.
 
Dan Feng
Employment - RemeGen Co., Ltd.
 
Jianmin Fang
Stock and Other Ownership Interests - RemeGen Co., Ltd., Yantai, China.